what phase is retatrutide in produces up to 30.3% weight loss 3 trial Retatrutide hits 28% weight loss

Industry analysts expect a potential approval window around 2026 to 2027, pending trial results and regulatory review

Helpful Hint: Split your abdomen into sections and switch injection spots each time to avoid the issue of lipohypertrophy

Ma Y, Lee E, Yoshikawa H, Noda T, Miyamoto J, Kimura I, et al

Do not rush the hold time

State regulations determine whether a synchronous consultation is required

Under the GLP-1 class framing, it is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2, anyone pregnant or breastfeeding, and anyone with prior serious GLP-1 hypersensitivity